Oakwood specializes in a full-service offering of end-to-end solutions to support all phases of long-acting injectable (LAI) development. As a experienced global CDMO partner focused on quality and timeline driven development, we will work with you from initial feasibility assessment, in vivo confirmation studies, GLP toxicology, product stability studies, scale-up and optimization, technology transfer to our GMP facility, and aseptic manufacturing of clinical and FDA-approved commercial supply.
